PI-RADS version 2: Detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer

Ji Won Seo, Su Jin Shin, Young Taik Oh, Dae Chul Jung, Nam Hoon Cho, Young Deuk Choi, Sung Yoon Park

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS. A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS. Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION. PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.

Original languageEnglish
Pages (from-to)W1-W9
JournalAmerican Journal of Roentgenology
Volume209
Issue number1
DOIs
Publication statusPublished - 2017 Jul

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Information Systems
Biopsy
Prostate
Neoplasms
Tumor Burden
Prostate-Specific Antigen
Prostatectomy
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Seo, Ji Won ; Shin, Su Jin ; Oh, Young Taik ; Jung, Dae Chul ; Cho, Nam Hoon ; Choi, Young Deuk ; Park, Sung Yoon. / PI-RADS version 2 : Detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer. In: American Journal of Roentgenology. 2017 ; Vol. 209, No. 1. pp. W1-W9.
@article{a0c15f61e6d14fa49f9aca3b1fbcb546,
title = "PI-RADS version 2: Detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer",
abstract = "OBJECTIVE. The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS. A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS. Clinically significant cancer was found in 87.4{\%} (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9{\%} (143/159); specificity, 69.6{\%} (16/23); positive predictive value, 95.3{\%} (143/150); negative predictive value, 50.0{\%} (16/32); and accuracy, 87.4{\%} (159/182). The corresponding values for reader 2 were 81.1{\%} (129/159), 82.6{\%} (19/23), 97.0{\%} (129/133), 38.8{\%} (19/49), and 81.3{\%} (148/182). For the experienced readers, 66.7-81.3{\%} of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION. PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.",
author = "Seo, {Ji Won} and Shin, {Su Jin} and Oh, {Young Taik} and Jung, {Dae Chul} and Cho, {Nam Hoon} and Choi, {Young Deuk} and Park, {Sung Yoon}",
year = "2017",
month = "7",
doi = "10.2214/AJR.16.16981",
language = "English",
volume = "209",
pages = "W1--W9",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "1",

}

PI-RADS version 2 : Detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer. / Seo, Ji Won; Shin, Su Jin; Oh, Young Taik; Jung, Dae Chul; Cho, Nam Hoon; Choi, Young Deuk; Park, Sung Yoon.

In: American Journal of Roentgenology, Vol. 209, No. 1, 07.2017, p. W1-W9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PI-RADS version 2

T2 - Detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer

AU - Seo, Ji Won

AU - Shin, Su Jin

AU - Oh, Young Taik

AU - Jung, Dae Chul

AU - Cho, Nam Hoon

AU - Choi, Young Deuk

AU - Park, Sung Yoon

PY - 2017/7

Y1 - 2017/7

N2 - OBJECTIVE. The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS. A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS. Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION. PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.

AB - OBJECTIVE. The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS. A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS. Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION. PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.

UR - http://www.scopus.com/inward/record.url?scp=85021077095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021077095&partnerID=8YFLogxK

U2 - 10.2214/AJR.16.16981

DO - 10.2214/AJR.16.16981

M3 - Article

C2 - 28418690

AN - SCOPUS:85021077095

VL - 209

SP - W1-W9

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 1

ER -